1. Discovery of 4-(3-aminopyrrolidinyl)-3-aryl-5-(benzimidazol-2-yl)-pyridines as potent and selective SST5 agonists for the treatment of congenital hyperinsulinism.
- Author
-
Zhao, Jian, Wang, Shimiao, Hee Kim, Sun, Han, Sangdon, Rico-Bautista, Elizabeth, Sturchler, Emmanuel, Nguyen, Julie, Tan, Hannah, Staley, Christine, Karin Kusnetzow, Ana, Betz, Stephen F., Johns, Michael, Goulet, Lance, Luo, Rosa, Fowler, Melissa, Athanacio, Jon, Markison, Stacy, Scott Struthers, R., and Zhu, Yunfei
- Subjects
- *
HYPERINSULINISM , *BEAGLE (Dog breed) , *SPRAGUE Dawley rats , *INSULIN receptors , *BLOOD sugar , *PEPTIDE receptors , *PHARMACEUTICAL chemistry - Abstract
[Display omitted] SST5 receptor activation potently inhibits insulin secretion from pancreatic β -cells, and an orally available nonpeptide selective SST5 agonist may be used to effectively manage the blood glucose levels of congenital HI patients to avoid severe hypoglycemia. Our medicinal chemistry efforts have led to the discovery of 4-(3-aminopyrrolidinyl)-3-aryl-5-(benzimidazol-2-yl)-pyridine analogs as potent SST5 agonists. This class of molecules exhibits excellent human SST5 potency and selectivity against SST1, SST2, SST3 and SST4 receptors. Leading compound 3-{4-[(3S)-3-aminopyrrolidin-1-yl]-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridin-3-yl-5-fluorobenzonitrile (28, CRN02481) showed limited off-target activity and good pharmacokinetic profiles in both male Sprague Dawley rats and Beagle dogs to advance into further preclinical evaluations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF